Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
IDH1 R132H Decitabine oligodendroglioma sensitive detail...
IDH1 mutant N/A oligodendroglioma not applicable detail...
IDH2 mutant N/A oligodendroglioma not applicable detail...
FGFR1 M563I FGFR1 K687E Futibatinib oligodendroglioma predicted - sensitive detail...
IDH1 mutant Vorasidenib oligodendroglioma predicted - sensitive detail...
IDH2 mutant Vorasidenib oligodendroglioma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00303849 Phase Ib/II Filgrastim Etoposide + Melphalan Carboplatin Pegfilgrastim Combination Chemotherapy With BBBD Followed By Sodium Thiosulfate in Treating Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma Completed USA 0
NCT01052363 Phase I Bevacizumab + Fosbretabulin OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas Withdrawn USA 0
NCT01140568 Phase II Nilotinib Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas Completed USA 0
NCT01188096 Phase II Poly ICLC A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas Completed USA 0
NCT01339039 Phase I Bevacizumab + Plerixafor Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma Terminated USA 0
NCT01392209 Phase I Bevacizumab Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma Completed USA 0
NCT01434602 Phase Ib/II Everolimus + Sorafenib Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas Completed USA 0
NCT01721577 Phase Ib/II AXL1717 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Terminated USA 0
NCT01884740 Phase Ib/II Bevacizumab + Cetuximab Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age Terminated USA 0
NCT01891747 Phase I Bevacizumab + Temozolomide A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma Completed USA 0
NCT01977677 Phase Ib/II Temozolomide Plerixafor Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma Completed USA 0
NCT01999270 Phase I Bevacizumab + Irinotecan Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors Completed USA 0
NCT02052778 Phase Ib/II Futibatinib A Study of TAS-120 in Patients With Advanced Solid Tumors Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 4
NCT02078648 Phase Ib/II SL-701 Poly ICLC Bevacizumab Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme Completed USA 0
NCT02101905 Phase I Lapatinib Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma Active, not recruiting USA 0
NCT02238496 Phase II Perifosine + Temsirolimus Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas Completed USA 0
NCT02423525 Phase I Afatinib Safety Study of Afatinib for Brain Cancer Completed USA 0
NCT02549833 Phase I GBM6-AD lysate protein vaccine + Poly ICLC Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma Active, not recruiting USA 0
NCT02924038 Phase I IMA950 + Poly ICLC Varlilumab A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) Active, not recruiting USA 0
NCT03220646 Phase II Abemaciclib Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors Active, not recruiting USA 0
NCT03343197 Phase I Ivosidenib Vorasidenib Study of AG-120 and AG-881 in Subjects With Low Grade Glioma Active, not recruiting USA 0
NCT03514069 Phase I Ruxolitinib Ruxolitinib + Temozolomide Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma Active, not recruiting USA 0
NCT03969706 Phase II Abemaciclib Abemaciclib in Patients With Oligodendroglioma Active, not recruiting USA 0
NCT03975829 FDA approved Dabrafenib + Trametinib Pediatric Long-Term Follow-up and Rollover Study Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 9
NCT03991832 Phase II Durvalumab + Olaparib Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors (SOLID) Recruiting CAN 0
NCT04164901 Phase III Vorasidenib Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN 3
NCT04295759 Phase I INCB7839 INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas Active, not recruiting USA 0
NCT04541082 Phase I ONC206 Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms Recruiting USA 0
NCT04691960 Phase II Metformin A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging Recruiting USA 0
NCT04908176 Phase I Avapritinib + Midazolam A Drug-drug Interaction Study of Avapritinib and Midazolam Completed USA 0
NCT04910022 Phase Ib/II NMS-03305293 + Temozolomide Lomustine Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma Recruiting USA | NLD | ITA 1
NCT04923126 Phase Ib/II PD-0325901 SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma Recruiting USA 0
NCT04978727 Phase I SurVaxM A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma Recruiting USA | CAN 0
NCT05267106 Phase II Pemigatinib Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU 2
NCT05297864 Phase II Niraparib PARP Inhibition for Gliomas (PI-4G or pi4g) Terminated USA 0
NCT05388435 Phase Ib/II SKL27969 Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients Terminated USA 0
NCT05561374 Phase I OKN-007 Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma Recruiting USA 0
NCT05956821 Phase Ib/II Bevacizumab + Cetuximab Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age Recruiting USA 0
NCT06258018 Phase Ib/II Niraparib + Temozolomide Niraparib and Temozolomide in Patients Glioblastoma (ONC-2022-001) Not yet recruiting ITA 0